Evidence map›Paper›PMID 39309420›Full record

ReviewAmerican journal of nuclear medicine and molecular imaging2024

The comparative utility of FAPI-based PET radiotracers over [

Shashi B Singh, Bimash B Shrestha, Om H Gandhi, Rajendra P Shah, Vaibhavi Mukhtiar, Cyrus Ayubcha, Vineet Desai, Christine E Eberts, Pranita Paudyal, Goody Jha and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Comparison of [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. Same-day dual-tracer PET/CT imaging with [Annals of nuclear medicine · 2025
    Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shashi B SinghStanford University School of Medicine Stanford, CA 94305, USA.
Bimash B ShresthaKIST Medical College Lalitpur, Bagmati 44700, Nepal.
Om H GandhiHospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA.
Rajendra P ShahDepartment of Cardiology, HCA Houston Healthcare Houston, TX 77004, USA.
Vaibhavi MukhtiarSaint Vincent Hospital 123 Summer Street, Worcester, MA 01608, USA.
Cyrus AyubchaHarvard Medical School 25 Shattuck Street, Boston, MA 02115, USA.
Vineet DesaiHarvard Medical School 25 Shattuck Street, Boston, MA 02115, USA.
Christine E EbertsUniversity of California, San Diego School of Medicine 9500 Gilman Dr, La Jolla, CA 92093, USA.
Pranita PaudyalBridgeport Hospital 267 Grant Street, Bridgeport, CT 06610, USA.
Goody JhaUniversity of California Davis Medical Center 4301 X Street, Sacramento, CA 95817, USA.
Anurag SinghTrijuddha Mahavir Prasad Raghuvir Ram Madhyamik Vidyalaya Birgunj, Parsa 44300, Nepal.
Yangyang ShiUniversity of Arizona College of Medicine 1501 N Campbell Avenue, Tucson, AZ 85724, USA.
Tushar KumarUniversity of Washington Medical Center, Main Hospital 1959 NE Pacific Street, Seattle, WA 98195, USA.

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Fibroblast activation protein (FAP) is a type II transmembrane serine protease overexpressed in cancer-associated fibroblasts (CAFs) and has been associated with poor prognosis. PET/CT imaging with radiolabeled FAP inhibitors (FAPI) is currently being studied for various malignancies. This review identifies the uses and limitations of FAPI PET/CT in malignancies and compares the advantages and disadvantages of FAPI and

Indexed as

[18F]-fluorodeoxyglucose ([18F]FDG)cancerdiagnosisFibroblast activation protein (FAP)fibroblast activation protein inhibitor (FAPI)malignancypositron emission tomography (PET)

Identifiers

PMID39309420
PMCPMC11411191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.